DiaSorin SpA
MIL:DIA

Watchlist Manager
DiaSorin SpA Logo
DiaSorin SpA
MIL:DIA
Watchlist
Price: 93.68 EUR -0.72% Market Closed
Market Cap: 5.2B EUR

DiaSorin SpA
Investor Relations

In the heart of the global healthcare landscape, DiaSorin SpA stands as a testament to innovation and precision in the field of biotechnology. Founded in 1968 in Italy, the company built its reputation on developing and producing diagnostic tests that help identify and monitor diseases. With a primary focus on immunodiagnostic and molecular diagnostic products, DiaSorin excels in creating high-quality, reliable solutions that clinicians and labs around the world depend on. Their product portfolio ranges widely, covering infectious diseases, oncology, endocrinology, and more. By leveraging cutting-edge research and development processes, DiaSorin not only prioritizes accuracy and efficiency in its testing solutions but also adapts to the ever-evolving demands of the medical world, cementing its role as a leader in diagnostic innovation.

From a business perspective, DiaSorin's revenue streams are deeply intertwined with its prowess in developing proprietary testing technologies, including both instruments and consumables. The company operates with a dual-channel business model where it sells diagnostic machines to laboratories, hospitals, and clinics while simultaneously providing the reagents and kits necessary for these machines' continuous operation. This approach ensures not only a sale of sophisticated equipment but also a recurring revenue stream from the consumables needed for diagnostics. With a strategic emphasis on research and partnerships, DiaSorin has expanded its reach globally, ensuring its products meet diverse regional healthcare requirements. Through a combination of robust product offerings and strategic global expansion, DiaSorin continues to thrive and maintain its position as a pivotal contributor to the field of diagnostic medicine.

Show more
Loading

Earnings Calls

2025 Q3
Dec 17, 2024
Show Transcript
Previous
Next
OVS Shows Strong Q3 Performance with Growth and Positive Outlook
2025 Q3
Dec 17, 2024

OVS reported a robust 13% increase in net sales for Q3, translating to an EBITDA growth of EUR 14 million. The total sales for the year are projected to exceed EUR 1.6 billion, with an EBITDA close to EUR 196 million and margins above 12%. In addition, the company expects revenue growth near last year’s figures for November to December despite higher sales last year. They are actively pursuing growth through acquisitions, particularly in enhancing their brand network. Concerns over inventory delays are expected to stabilize with improved logistics, while labor costs are anticipated to rise by around 3% next year.

Show Full Analysis

Management

Mr. Carlo Rosa
CEO, GM & Executive Director
No Bio Available
Dr. Chen Menachem Even
Chief Commercial Officer, Senior Corporate VP of Commercial Operations & Executive Director
No Bio Available
Mr. Piergiorgio Pedron
Senior Corporate VP, CFO & Corporate Accounting Documents Officer
No Bio Available
Mr. Fabrizio Piercarlo Bonelli
Corporate VP & Chief Technology Officer
No Bio Available
Dr. Riccardo Fava
Corporate Vice President of Communication, ESG & Investor Relations
No Bio Available
Mr. Ulisse Spada
Corporate VP, Head of the Legal Department, Secretary & General Counsel
No Bio Available
Ms. Amelia Parente
Senior Corporate Vice President of Human Resources
No Bio Available
Mr. Angelo Rago
President of Luminex Corporation
No Bio Available

Contacts

Address
VERCELLI
Saluggia
Via Crescentino snc
Contacts
+390161487526.0
www.diasorin.com